Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy (PTLD-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02042391
Recruitment Status : Recruiting
First Posted : January 22, 2014
Last Update Posted : July 24, 2018
Sponsor:
Information provided by (Responsible Party):
Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : July 2022
  Estimated Study Completion Date : December 2022
Publications: